So on Friday, the shares rocketed on the back of this press release "Second Sight Medical Products (NASDAQ:EYES) a leading developer and marketer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced U.S. The current market cap of EYES is $134 million. The Argus 2 is a tiny implant that goes in behind the eye and is then combined with patient-worn camera glasses to help provide a form of vision the patient otherwise would not have. In 2011, Second Sight achieved the first-ever regulatory approval for a technology able to restore useful vision to people with retinitis pigmentosa. Robert Greenberg, Aaron Mendelsohn and Gunnar Bjorg, with the team working tirelessly to bring Second Sight’s vision-restoring innovation to fruition. In 1998, the partnership expanded to include Dr. Sam Williams and pioneering medical philanthropist Dr. From the company's own website it states "A deeply purpose-driven company from the start, Second Sight has its roots in a forward-looking partnership between retinitis pigmentosa sufferer Dr. Second Sight Medical is a medical device company specializing in helping create prosthetic devices to help restore vision to blind people. Shares in EYES soared over 300%, closing at $5.79. Second Sight Medical (EYES) shares soared on Friday as the company announced it had received FDA approval for its Argus 2 retinal prosthesis system. EYES is still gaining on the back of FDA news late last week. The braod market is certainly helping with tech stocks up nearly 4% as the Nasdaq recovers ground.
#EYES STOCK UPDATE#
Update March 9: Shares in EYES continue to trade strongly, up 28% at $15 at the time of writing.
#EYES STOCK CODE#
SEC CFR Title 17 of the Code of Federal Regulations. SEC.report is not affiliated with the U.S. 🔎 conduct a search for additional similar companiesĭata is automatically aggregated and provided “as is” without any representations or warranties, express or implied.
Second & Ash Opportunity Zone Fund, LLC of DELAWARE Second Avenue Tower Limited Partnership of DELAWARE Second Foundation Partners, LLC of DELAWARE SECOND SIGHT MEDICAL PRODUCTS EQUITY WARRANTS EXP 14 MARCH 2024 Second Sight Medical Products Inc *W EXP Second Sight Medical Products Equity Warrants Exp 14 March 2024 *W EXP Second Sight Medical Products / Second Sight Medical Products, Inc. Where To Trade EYESW / VANIW / EYES / VANI Market / Outlet Geographically, the company operates in the United States, Italy, France and Germany, of which key revenue is derived from the United States.ĭirector and Acting Chief Executive Officer ĭirector, Chief Executive Officer and President Ĭhief Financial Officer and Principal Accounting Officer Ĭompany Names & Stock Symbols Larson Alexandra L.P. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP.
Second Sight Medical Products Inc develops, manufactures and markets implantable prosthetic devices, to create an artificial form of useful vision for blind individuals.
#EYES STOCK REGISTRATION#
This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Second Sight Medical Products Inc. For financial reporting, their fiscal year ends on December 31st. Second Sight Medical Products Inc is primarely in the business of electromedical & electrotherapeutic apparatus. Second Sight Medical Products Inc is incorporated in the state of California.
0 kommentar(er)
